First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with artesunate‐amodiaquine (AS‐AQ) (very low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal ALT increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal AST increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether pyronaridine‐artesunate (PY‐AS) changes first treatment, abnormal bilirubin increase (42 days) compared with mefloquine plus artesunate (MQ + AS) (very low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) leads to higher first treatment, abnormal ALT increase compared with other antimalarials (high certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) probably leads to higher first treatment, abnormal AST increase compared with other antimalarials (moderate certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase compared with other antimalarials (moderate certainty).
1 finding from 1 review
Subsequent treatment(s), abnormal ALT increase · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal ALT increase compared with other antimalarials (low certainty).
1 finding from 1 review
Subsequent treatment(s), abnormal AST increase · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal AST increase compared with other antimalarials (low certainty).
1 finding from 1 review
Subsequent treatment(s), abnormal bilirubin increase · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal bilirubin increase compared with other antimalarials (low certainty).
1 finding from 1 review
First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Abnormal dreams · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine led to higher abnormal dreams compared with doxycycline; GRADE not reported.
1 finding from 1 review
Abnormal thoughts or perceptions · Non‐immune adults and children travelling to malaria‐endemic settings
Mefloquine showed no clear difference in abnormal thoughts or perceptions compared with doxycycline; GRADE not reported.
1 finding from 1 review
Abnormal dreams · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine led to higher abnormal dreams compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Abnormal thoughts or perceptions · non‐immune adults and children travelling to or living in malaria‐endemic settings
Mefloquine showed no clear difference in abnormal thoughts or perceptions compared with atovaquone‐proguanil; GRADE not reported.
1 finding from 1 review
Intervention not reported
Index Test result · of people with HIV‐negative or unknown HIV status who are considered eligible for systematic screening for tuberculosis disease. Role of…
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported